Table 2

Proposed guidelines for MRD follow-up using CBFB-MYH11, RUNX1-RUNX1T1, PML-RARA, NPM1c, or WT1 as molecular markers

Sampling interval, moRDF, %tm, d
CBFB-MYH11    
    PB 6* 90 180 
    BM Avoid   
RUNX1-RUNX1T1    
    PB 3 85 65 
    BM 4 95 85 
PML-RARA    
    PB 1 75 35 
    BM 2 90 60 
NPM1c/FLT3-ITD−    
    PB 4 90 60 
    BM 6 90 120 
NPM1c/FLT3-ITD+    
    PB 3 90 65 
    BM 4 90 105 
WT1    
    PB 2 85 45 
    BM 4 95 75 
Sampling interval, moRDF, %tm, d
CBFB-MYH11    
    PB 6* 90 180 
    BM Avoid   
RUNX1-RUNX1T1    
    PB 3 85 65 
    BM 4 95 85 
PML-RARA    
    PB 1 75 35 
    BM 2 90 60 
NPM1c/FLT3-ITD−    
    PB 4 90 60 
    BM 6 90 120 
NPM1c/FLT3-ITD+    
    PB 3 90 65 
    BM 4 90 105 
WT1    
    PB 2 85 45 
    BM 4 95 75 

RDF indicates relapse detection frequency; and tm, median time from molecular to hematologic relapse.

*

One additional MRD sampling recommended 3 months after end of chemotherapy to detect early relapses.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal